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Background: Previous studies have examined the associations between polymorphisms of adiponectin gene
(ADIPOQ) and cardiovascular disease (CVD), but those studies have been inconclusive. The aim of this study was to
access the relationship between three single nucleotide polymorphisms (SNPs), +45 T>G (rs2241766), +276 G> T
(rs1501299) and -11377 C>G (rs266729) in ADIPOQ and CVD.
Methods: A comprehensive search was conducted to identify all studies on the association of ADIPOQ gene
polymorphisms with CVD risk. The fixed and random effect pooled measures (i.e. odds ratio (OR) and 95%
confidence interval (CI)) were calculated in the meta-analysis. Heterogeneity among studies was evaluated using Q
test and the I2. Publication bias was estimated using modified Egger’s linear regression test.
Results: Thirty-seven studies concerning the associations between the three polymorphisms of ADIPOQ gene and
CVD risk were enrolled in this meta-analysis, including 6,398 cases and 10,829 controls for rs2241766, 8,392 cases
and 18,730 controls for rs1501299 and 7,835 cases and 14,023 controls for rs266729. The three SNPs were
significantly associated with CVD, yielding pooled ORs of 1.22 (95%CI: 1.07, 1.39; P= 0.004), 0.90 (95%CI: 0.83, 0.97;
P= 0.007) and 1.09(95%CI: 1.01, 1.17; P= 0.032) for rs2241766, rs1501299 and rs266729, respectively. Rs2241766 and
rs1501299 were significantly associated with coronary heart disease (CHD), yielding pooled ORs of 1.29 (95%CI: 1.09,
1.52; P= 0.004) and 0.89 (95%CI: 0.81, 0.99; P= 0.025), respectively. The pooled OR for rs266729 and CHD was 1.09
(95%CI: 0.99, 1.19; P= 0.090). Significant between-study heterogeneity was found in our meta-analysis. Evidence of
publication bias was observed in the meta-analysis.
Conclusions: The present meta-analysis showed that the associations between rs2241766, rs1501299 and rs266729
in the ADIPOQ and CVD were significant but weak. High quality studies are still needed to confirm the associations,
especially for rs2241766.
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Adiponectin is a 30-kDa protein that consists of an N-
terminal collagenous domain and a C-terminal globular
domain[1], with circulating levels ranging from 0.5 to
30 μg/ml and accounting for 0.05% of total plasma pro-
tein[2,3].
Adiponectin plays a role in preventing atherosclerosis.
Epidemiology studies have found that adiponectin levels* Correspondence: gudf@yahoo.com
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reproduction in any medium, provided the origwere associated with risk of cardiovascular disease
(CVD). Some cross-sectional studies have demonstrated
that hypoadiponectinemia was associated with the preva-
lence of CVD[4-7]. Prospective studies also found sig-
nificant inverse association between adiponectin and
CVD. Health Professionals Follow-up Study found that
high plasma adiponectin levels were associated with
lower risk of myocardial infarction (MI) over a follow-up
period of 6 years among men without previous cardio-
vascular disease[8]. The Nurses’ Health Study recently
found that high levels of total adiponectin wereLtd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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14 years of follow-up [9].
There have been a number of studies reported that cer-
tain polymorphisms in the adiponectin coding gene ADI-
POQ were strongly associated with adiponectin levels [10-
13]. A recent genome wide association study (GWAS)
identified that a single nucleotide polymorphism (SNP)
rs266717 at the ADIPOQ locus demonstrated the stron-
gest associations with adiponectin levels (P-combined= 9.2
× 10−19, n = 14,733) [14]. In that study, the authors also
re-evaluated other SNPs in ADIPOQ and found that
rs266729 and rs182052 showed significant association.
Previous studies have examined the association of several
polymorphisms in the ADIPOQ gene, including rs822395
(−4034A>C), rs822396 (−3964A>G), +2019delA,
rs17300539 (−11391 G>A), rs266729 (−11377 C>G),
rs2241766 (+45 T>G) and rs1501299 (+276 G>T), with
CVD and subclinical CVD [15]. The three SNPs,
rs266729, rs2241766 and rs1501299, were most widely
studied.
Lacquemant et al. reported that rs2241766 was asso-
ciated with an increased risk of coronary artery disease
among patients with type 2 diabetes[16]. Bacci et al.
reported that polymorphism rs1501299 was associated
with a decreased coronary artery disease risk [17]. How-
ever, these early studies have been limited by the small
sample size and case–control design. Subsequent
researches on this issue reported different results. A
large genetic association case–control study conducted
by Chiodini et al. confirmed the association for
rs1501299, but SNP rs2241766 showed no significant as-
sociation [18]. The studies conducted by Pischon et al.
also failed to confirm these associations [9]. The result
for rs266729 has also been inconsistent [19-21].
Meta-analysis is a powerful tool for summarizing
results from different studies by producing a single esti-
mate of the major effect with enhanced precision. In this
study, we conducted a meta-analysis to examine the
associations between the three SNPs in the ADIPOQ
gene and CVD.
Methods
Retrieval of published studies
Two independent reviewers (Zhang and Mo) conducted
a systematic computerized literature search for papers
published before February 12, 2012. PubMed, Embase
and Wanfang databases were searched, using various
combinations of keywords, such as ‘cardiovascular dis-
ease’ or ‘coronary heart disease’ or ‘coronary artery dis-
ease’ or ‘myocardial infarction’ or ‘stroke’ combined with
‘ADIPOQ’ or ‘APM1’ or ‘ACDC’ or ‘adiponectin’ and
‘polymorphism’ and ‘genetic association’, without lan-
guage restriction. The full texts of the retrieved articles
were read to decide whether information on the topic ofinterest should be included. The reference lists of the
retrieved articles as well as those of review articles and
previous meta-analyses on this topic were searched to
identify other studies that were not identified initially.
Articles were included in the meta-analysis if they exam-
ined the hypothesis that ADIPOQ polymorphisms were
associated with CVD using case–control or cohort de-
sign, and had sufficient published data on the genotypes
or allele frequencies for determining an estimate of rela-
tive risk (i.e. odds ratio (OR)) and confidence interval
(CI). Our meta-analysis was conducted according to the
Meta-analysis of Observational Studies in Epidemiology
(MOOSE) guidelines [22].
Data extraction
Two reviewers (Zhang and Mo) independently examined
the retrieved articles using a data collection form, in
order to extract the information needed. From each
study, the following data were abstracted: first author,
year of publication, country of the population studied,
study subjects and main outcomes, the mean age and
body mass index (BMI) and the percentage of men in
case and control groups, polymorphisms tested, geno-
typing methods, the number of persons with different
genotypes in cases and controls, and main results. Fol-
lowing data extraction, the reviewers checked for any
discordance until a consensus was reached.
Quality score assessment
Quality of studies was also independently assessed by
the same two reviewers, using guidelines proposed by
the NCI-NHGRI Working Group on Replication in As-
sociation Studies [23]. These guidelines provided a
checklist of 53 conditions for authors, journal editors
and referees to allow clear and unambiguous interpret-
ation of the data and results of genome-wide and other
genotype–phenotype association studies. The first 34
conditions were considered for quality assessment of
each study in our meta-analysis. One score is assigned
to each condition. If one study met a requirement, it
gained 1 score and otherwise, it gained 0. The sum of
the score for each study was described as total quality
score.
Statistical analysis
The OR was used to compare alleles between cases and
controls. We computed the genetic contrast of the mu-
tant alleles (G for rs2241766, T for rs1501299 and G for
rs266729) versus the wildtype alleles. In secondary ana-
lyses, we calculated specific ORs according to the racial
descent of subjects (separated analyses for Caucasian,
East Asian, West Asian and African populations), study
subjects (normal subjects or subjects with type 2 dia-
betes or other diseases), sample size (<1000 or ≥1000),
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assay or other). The association for coronary heart
disease (CHD) was also examined. We assessed the pres-
ence of between-study heterogeneity using the chi-
square based Cochran’s Q statistic. The inconsistency
index I2 (ranging from 0 to 100%) was also calculated,
where higher values of the index (I2> 50%) indicate the
existence of heterogeneity[24]. Publication bias was
assessed with Egger regression test [25]. The pooled OR
was calculated by the inverse-variance weighted method,
and the significance of the pooled OR was tested by Z
statistic. The combined ORs along with their 95% CIs
were estimated using the fixed effects and random
effects method. The random-effects method[26], which
in the presence of heterogeneity, is more appropriate as
it is prudent to take into account an estimate of the be-
tween-study variance (I2). On the other hand, the ran-
dom effects hypothesis is appropriate for clinical trials
but results in relatively reduced power for genetic asso-
ciation/GWAS detection of SNPs which show associ-
ation in at least one study [27]. The random effects
model has less power to detect effects than fixed effects
in almost all situations [28]. To examine specific subsets
in these studies, separate analyses were undertaken. This
was achieved by performing a sensitivity analysis, in
which an individual study was removed each time to as-
sess the influence of each study. Likewise, a cumulative
analysis was performed according to the ascending date
of publication to identify the influence of the first pub-
lished study on the subsequent publications and the evo-
lution of the combined estimate over time [29]. For all
analyses performed here, the statistical package Stata 10
(Stata Corporation, College Station, Texas, USA) was
used. In all analyses statistically significant results were
declared as those with a P value< 0.05, except for tests
of publication bias where 0.1 was used as significant
level.Results
After the literature searching and the subsequent screen-
ing, we came up with 34 research papers consisting of
37 case–control or cohort studies concerning the associ-
ation of rs2241766 or rs1501299 or rs266729 poly-
morphisms with CVD (Figure 1). The detailed
characteristics of each study were summarized, including
authors, publication year, mean age, percentage of men,
sample size, genotyping method and study population
(Table 1). We also summarized the mean BMI in case
and control groups and genotype data in case and con-
trol groups (Additional file 1: Table S1) and the main
results of each study (Additional file 2: Table S2). Details
of the quality score assessment were presented in Add-
itional file 3: Table S3.Meta-analysis for rs2241766 polymorphism
The 24 retrieved studies that investigated the associ-
ation of rs2241766 with CVD contained information
about 6,398 cases and 10,829 control subjects
(Table 2). The pooled frequency of the minor G al-
lele in controls was 15.7%.
Figure 2 showed that the combined ORs (fixed-effects
and random-effects method) for the rs2241766G allele on
CVD were 1.12 (95%CI: 1.05, 1.19; P< 0.0001) and 1.22
(95%CI: 1.07, 1.39; P=0.004). There was a significant be-
tween-study heterogeneity as indicated by the P value of
the corresponding test (P< 0.001) and the value of the I2
index (I2 =74.2%). The sensitivity analysis revealed that
there was not a single study influencing the result signifi-
cantly. Cumulative analysis found the influence of the first
published study on the subsequent publications and the
evolution of the combined estimate over time. Lacquemant
et al. reported the significant association in 2003 [14], while
the subsequent publications added to the meta-analysis, the
significance disappeared. The overall estimation became
significant after the large study reported by Chiodini et al.
in 2010 included in the analysis [16]. Evidence of publica-
tion bias was found in the studies (Egger’s test, P=0.007).
The association for CHD alone was also significant, with an
OR of 1.29(95%CI: 1.09, 1.52) (Table 2).Meta-analysis for rs1501299 polymorphism
Twenty-seven studies investigating the association of
rs1501299 with CVD were enrolled in this meta-analysis,
containing about 8,392 cases and 18,730 control subjects
(Table 2). The pooled frequency of the T allele in control
groups was 28.3%.
A significant association was observed between the
rs1501299T allele and risk of CVD (Figure 3), yielding
overall ORs (fixed-effects and random-effects method) of
0.93 (95%CI: 0.89, 0.97; P= 0.001) and 0.90 (95% CI: 0.83,
0.97; P= 0.007). Significant heterogeneity was observed
(I2 = 58.0%, P< 0.001). The sensitivity analysis revealed
that there was not a single study influencing the result
significantly. Cumulative analysis did not find the influ-
ence of the first published study on the subsequent publi-
cations and the evolution of the combined estimate over
time. There was publication bias in the studies (Egger’s
test, P= 0.077). The combined OR for rs1501299 and
CHD was 0.89(95%CI: 0.81, 0.99) (Table 2).Meta-analysis for rs266729 polymorphism
Twenty studies including about 7,835 cases and 14,023
controls were enrolled in this meta-analysis for the associ-
ation between rs266729 and CVD (Table 2). For all the
studies included, we found that the control groups were in
HWE. The pooled frequency of the G allele was 24.8% in
the control groups.
99 potentially relevant articles 
37 studies were finally included: 
24 studies for +45T>G (rs2241766) 
27 studies for +276G>T (rs1501299) 
20 studies for -11377C>G (rs266729) 
3 papers each consist of 2 studies 
34 potentially appropriate articles 
65 papers excluded for: 
Non-association studies 
Association studies for other diseases 
Association studies for other polymorphisms 
Not original studies (reviews, letters, etc.) 
Detail genotype distribution data 
unavailable
Duplicates removed 
Potentially relevant articles identified in 
database search  
Pubmed 50 articles 
Embase 66 articles 
Wanfang 12 articles 
Figure 1 Flow diagram for study selection process in the meta-analysis of ADIPOQ gene polymorphisms and CVD.
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cant, with ORs (fixed-effects and random-effects
method) of 1.07 (95%CI: 1.02, 1.13; P = 0.003) and
1.09(95%CI: 1.01, 1.17; P = 0.032), and significant het-
erogeneity (I2 = 53.6%, P = 0.002) (Figure 4). By per-
forming subgroup analyses we found that the East
Asian studies indicated significant association (OR =
1.29, 95% CI: 1.18, 1.42). Heterogeneity disappeared
in this subgroup analysis, I2 indexes equal to 26.1%
and 0 for European subgroup and Asian subgroup,
respectively (Table 2). The sensitivity analysis revealed
that there was not a single study influencing the re-
sult significantly. Cumulative analysis did not find the
influence of the first published study on the subse-
quent publications and the evolution of the combined
estimate over time. The results of Egger’s test did not
suggest publication bias in the studies, P = 0.624. No
significant association was found between rs266729
and the risk of CHD (OR= 1.09, 95% CI: 0.99, 1.19,
random-effects method), with significant between-
study heterogeneity (I2 = 51.8%, P = 0.023) (Table 2).Discussion
The present meta-analysis, involving 6 to 8 thousand
cases and more than 10 thousand controls for each poly-
morphism, provides a clear indication of significant asso-
ciations between the three SNPs, rs2241766, rs1501299
and rs266729, in ADIPOQ and CVD. The findings of
this study suggest that the rs2241766G allele and
rs266729G allele increase odds of CVD, while the
rs1501299T allele decreases. Rs2241766 and rs1501299
are significantly associated with CHD. However, the
results were nearly “crude” ones, other important risk
factors for CVD or CHD might diminish the significance
of the results, so the associations were significant but
weak. Nevertheless, the magnitude of these associations
is in the range of all positive associations found with
SNPs in multifactorial polygenic disorders, even with the
“top ten” SNPs from GWAS.
Qi et al. have conducted a meta-analysis to summarize
the association between rs1501299 and CVD risk among
diabetic patients [34]. 827 CVD cases and 1,887 CVD-free
control subjects were included in their meta-analysis.
Table 1 Characteristics of the eligible studies included in the meta-analysis





scoreCase Control Case Control Case Control
Lacquemant[16] Switzerland 2003 107 181 / / / / T2D CAD Other 9
Lacquemant[16] France 2003 55 134 / / / / T2D CAD Other 9
Bacci[17] Italy 2004 142 234 64.0 60.0 64.1 43.2 T2D CHD Other 8
Ohashi [30] Japan 2004 383 368 63.0 62.3 70.5 65.2 General CAD TaqMan 7
Stenvinkel [31] America 2004 63 141 / / / / Renal disease CVD Other 7
Filippi [32] Italy 2005 580 466 60.3 50.9 76.9 49.6 General CAD Other 9
Ru [33] China 2005 131 136 51.3 50.6 56.2 52.9 General CHD TaqMan 6
Qi [21] America 2005 239 640 59.6 55.0 100 100 T2D CVD TaqMan 10
Qi [34] America 2006 285 704 47.0 44.0 0 0 T2D CVD TaqMan 10
Gable [35] UK 2006 266 2727 56.0 56.6 100 100 General CVD PCR-RFLP 12
Gable [35] UK 2006 530 564 56.0 56.6 100 100 General MI PCR-RFLP 12
Wang [36] China 2006 120 131 / / / / General CHD PCR-RFLP 7
Hegener[37] America 2006 341 341 60.2 60.1 100 100 General MI TaqMan 11
Hegener[37] America 2006 259 259 62.1 61.7 100 100 General Stroke TaqMan 11
Jung[38] Korea 2006 88 86 60.4 53.4 71.6 50 General CAD TaqMan 8
Pischon[39] America 2007 1036 2071 62.9 62.8 51.7 51.7 General CHD TaqMan 11
Lu[40] China 2007 131 135 58.4 60.7 68.9 62.6 General CHD PCR-RFLP 7
Liang[41] China 2008 100 100 45.7 60.8 66.0 65.0 General CHD PCR-RFLP 6
Yamada[42] Japan 2008 313 971 67.0 68.2 61.7 48.7 MetS ACI Other 9
Oguri[19] Japan 2009 773 1114 64.8 68.3 77.2 50.8 MetS MI Other 10
Chang[43] China 2009 600 718 63.8 51.1 78.3 53.4 General CAD PCR-RFLP 9
Foucan[44] France 2009 57 159 68.0 63.0 51.0 36.0 T2D CAD TaqMan 7
Zhang[45] China 2009 205 130 65.0 63.0 63.4 50.4 General CHD PCR-RFLP 8
Zhong[46] China 2010 198 237 60.6 54.5 54.0 46.0 General CAD TaqMan 10
De Caterina[47] Italy 2010 1864 1864 39.5 39.6 88.8 88.8 General MI Other 13
Xu[48] China 2010 153 73 66.3 66.3 53.6 53.4 General CHD PCR-RFLP 8
Al-Daghri[49] Saudi Arabia 2010 123 295 69.4 60.7 60 70 T2D CAD PCR-RFLP 8
Prior[20] UK 2010 85 298 71.0 68.2 63.6 50.6 General CHD PCR-RFLP 7
Chiodini[18] Italy 2010 503 503 56.5 54.7 89.3 95.8 General MI TaqMan 10
Rodriguez[50] Spain 2010 119 555 / / / / RA CVD TaqMan 9
Leu[51] China 2010 80 3330 59.1 50.0 52.5 45.3 General stroke Other 10
Liu[52] China 2010 302 338 65.7 64.4 63.9 62.1 General stroke PCR-RFLP 9
Chen[53] China 2010 357 345 63.6 53.7 60.2 60.9 General stroke TaqMan 8
Sabouri[54] UK 2011 329 106 58.4 47.6 64.1 56.3 General CAD PCR-RFLP 8
Esteghamati[55] Iran 2011 144 127 61.1 51.1 38.6 55.9 General CAD PCR-RFLP 10
Boumaiza[56] Tunisia 2011 212 104 60.6 59.4 69.3 55.8 General CAD PCR-RFLP 10
Katakami[57] Japan 2012 213 2424 58.1 54.6 66.2 60.7 T2D CVD Other 11
ACI = atherothrombotic cerebral infarction; CAD= coronary artery disease; CHD= coronary heart disease; CVD= cardiovascular disease; MI =myocardial infarction;
MetS =metabolic syndrome; RA = rheumatoid arthritis; T2D = type 2 diabetes.
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nificantly associated with ~45% reduction in CVD risk. A
recent meta-analysis for rs1501299 and CVD also reported
the protect effect of rs1501299T allele in type 2 diabetes
population [58]. Our meta-analysis included more studies
and collected more information than previous meta-ana-
lyses. We also evaluated the association for the SNPrs1501299 under a recessive model among type 2 diabetic
patients. The result was very similar to that of previous
meta-analyses, with an OR of 0.71(95%CI: 0.56, 0.91). Pre-
vious meta-analysis did not evaluate the associations be-
tween rs2241766 and rs266729 and CVD risk. According
to our results, significant associations were also observed
for these two important SNPs.
Table 2 Meta-analysis of ADIPOQ gene polymorphisms and CVD
+45 T>G +276 G> T −11377 C>G
No.
studies
Sample size Per allele risk I2% No.
studies
Sample size Per allele risk I2% No.
studies
Sample size Per allele risk I2%
Case/control OR(95%CI) P Case/control OR(95%CI) P Case/control OR(95%CI) P
Overall 24 6398/10829 1.22(1.07-1.39) 0.004 74.2 27 8392/18730 0.90(0.83-0.97) 0.007 58.0 20 7835/14023 1.09(1.01-1.17) 0.032 53.6
CHD 17 4685/5881 1.29(1.09-1.52) 0.004 76.9 18 6585/7760 0.89(0.81-0.99) 0.025 65.1 11 5687/7431 1.09(0.99-1.19) 0.090 51.8
Population
European origin 12 3751/8269 1.10(0.94-1.27) 0.226 63.1 15 6306/11254 0.95(0.89-1.02) 0.155 33.8 14 5729/10924 1.01(0.94-1.08) 0.880 26.1
East Asian 7 1813/1766 1.19(0.91-1.56) 0.209 82.6 9 1637/6948 0.83(0.68-1.02) 0.074 73.3 6 2106/3099 1.29(1.18-1.42) <0.001 0
West Asian 3 565/531 2.07(1.33-3.22) 0.001 59.5 2 237/424 0.75(0.41-1.36) 0.337 81.4 0
African 2 269/263 1.38(0.79-2.41) 0.257 36.7 1 212/104 0.75(0.53-1.07) 0.110 / 0
Study subjects
Normal subjects 17 5501/8723 1.20(1.03-1.41) 0.018 78.7 17 6949/13367 0.92(0.84-1.01) 0.082 63.3 12 5897/9627 1.09(1.00-1.19) 0.042 46.6
Subjects with T2D 6 834/1965 1.18(0.90-1.54) 0.222 52.2 8 1261/4667 0.88(0.76-1.02) 0.098 47.0 4 672/1615 0.87(0.75-1.01) 0.07 0
Subjects with MetS 0 0 2 1084/2085 1.29(1.15-1.46) <0.001 0
Subjects with RD 1 63/141 2.06(1.10-3.83) 0.023 / 1 63/141 0.64(0.39-1.03) 0.063 / 1 63/141 1.45(0.90-2.32) 0.129 /
Subjects with RA 0 1 119/555 0.79(0.57-1.09) 0.151 / 1 119/555 1.01(0.73-1.40) 0.941 /
Sample size
More than 1000 5 2911/6409 1.01(0.80-1.28) 0.912 84.5 8 5006/13809 0.93(0.84-1.04) 0.216 65.2 7 5274/9800 1.13(1.03-1.25) 0.014 62.5
Less than 1000 19 3487/4420 1.30(1.12-1.52) 0.001 63.9 19 3386/4921 0.87(0.78-0.97) 0.015 56.0 13 2561/4223 1.04(0.93-1.18) 0.488 49.6
Genotyping method
TaqMan 9 3101/4986 1.13(0.94-1.37) 0.188 70.8 10 3362/5571 0.93(0.85-1.01) 0.098 31.6 9 3284/5572 1.00(0.91-1.10) 0.959 33.8
PCR-RFLP 11 2942/5167 1.25(1.01-1.56) 0.043 80.6 9 1958/4516 0.80(0.68-0.94) 0.006 63.1 5 1388/4057 1.19(1.03-1.39) 0.023 43.2
Other 4 355/676 1.44(0.99-2.11) 0.058 54.3 8 3072/8643 0.97(0.83-1.14) 0.728 64.7 6 3163/4394 1.15(0.98-1.35) 0.090 64.0
MAF=minor allele frequency; OR= odds ratio; CI = confidence interval; NA = not available; T2D = type 2 diabetes; MetS =metabolic syndrome; RD = renal disease; RA = rheumatoid arthritis; I2: The inconsistency index for



















NOTE: Weights are from random effects analysis















































































































































































































Figure 2 Meta-analysis for the relationship between rs2241766 and CVD risk. Year represents publish year. The solid squares represent
odds ratios (ORs) from individual studies; the diamonds are shown as overall effect. The combined ORs along with their 95% CIs were in the
contrast of G allele vs. T allele and estimated using the random-effects method.
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http://www.biomedcentral.com/1471-2350/13/40The findings of our study may shed light on the under-
lying disease mechanism in CVD. Previous studies and
meta-analysis demonstrated that rs1501299T carriers had
higher adiponectin levels [10,59], which were associated
with lower odds of CVD [8,9,60,61]. Besides, these SNPs
were reported to be associated with many conventional
CVD risk factors, such as hypertension, obesity, diabetes
mellitus, insulin restriction and metabolic syndrome. The
HOMA-IR (homeostasis model assessment of insulin re-
sistance) index was higher in rs1501299GG carriers as
compared with TG and TT subjects, indicating higher insu-
lin sensitivity in carriers of allele T, the same allele that
showed an association with increased adiponectin levels[59]. Rs1501299 was also found to be associated with the
presence of hypertension in metabolic syndrome indivi-
duals [62]. The rs266729G allele was reported to be signifi-
cantly associated with higher odds of hypertension in Hong
Kong Chinese, after adjusting for covariates. In stepwise
multiple logistic regression, this SNP was a significant inde-
pendent risk factor of hypertension, together with age, body
mass index, triglycerides, and insulin resistance index. Also,
rs266729 was significantly associated with adiponectin level
after adjusting for covariates [63]. Previous meta-analysis
also detected a significant association between rs266729
and an increased risk of T2D [64]. As mentioned above, the
effect of rs1501299 and rs266729 on CVD risk might be
NOTE: Weights are from random effects analysis







































































































































































































































Figure 3 Meta-analysis for the relationship between rs1501299 and CVD risk. Year represents publish year. The solid squares represent
odds ratios (ORs) from individual studies; the diamonds are shown as overall effect. The combined ORs along with their 95% CIs were in the
contrast of T allele vs. G allele and estimated using the fixed-effects method.
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http://www.biomedcentral.com/1471-2350/13/40regulated by adiponectin concentrations, as well as other
CVD risk factors. Nevertheless, these particular SNPs are
far from being the most influent on adiponectin levels and
CVD risk factors, and the association is weak and/or con-
troversial, especially for rs266729 and rs2241766.
Several potential limitations of our study should be
noted. First, significant between-study heterogeneities
were observed in our study, we tried to explored the
source of heterogeneities with factors such as ethnicity,
study subjects, sample size, genotyping methods in the
subgroup analyses. However, for rs2241766 and
rs1501299 polymorphisms, significant heterogeneities
still remained, only the heterogeneity for rs266729 disap-
peared by performing subgroup analyses according toethnicity. Second, as significant publication bias was
observed in the analysis of rs2241766, the association for
this SNP still needs to be confirmed in future studies.
Third, the eligible studies in our research were mainly
from Asia and Europe, data of other populations, like
African, was limited. Fourth, because we did not have
access to individual data, we could not control for popu-
lation stratification, nor could we adjust for variables in
possible intermediate pathways. Finally, we should
realize that the results might be distorted by potential
weakness and biases of genetic association studies, such
as genotyping error, phenotype misclassification, popula-
tion stratification, gene-gene or gene-environment inter-
active effect, and selective reporting biases [29,65].
NOTE: Weights are from random effects analysis















































































































































































Figure 4 Meta-analysis for the relationship between rs266729 and CVD risk. Year represents publish year. The solid squares represent odds
ratios (ORs) from individual studies; the diamonds are shown as overall effect. The combined ORs along with their 95% CIs were in the contrast of
G allele vs. C allele and estimated using the random-effects method.
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functional variants. More studies are needed to eluci-
date the complete range of the signal transduction
pathways that the variant is implicated in, and thus,
throw light in the underlying molecular mechanisms
that confer susceptibility to CVD. The particular
polymorphism associated with CVD itself may not
play a functional role, but rather it may be located
physically close to the actual disease-predisposing
gene.
In addition to the genetic markers described in this
meta-analysis, many other polymorphisms have been
studied. Those polymorphisms may be candidates for a
multivariate analysis. Future haplotypic approaches and
further haplotype-based meta-analyses will provide more
powerful and informative results than current single
genotype-based data.Conclusions
The present meta-analysis showed that the associations
between rs2241766, rs1501299 and rs266729 in the
ADIPOQ and CVD were significant but weak. The
rs2241766G allele and rs266729G allele increase risk of
CVD, while the rs1501299T allele decreases. High qual-
ity studies are still needed to confirm the associations,
especially for rs2241766.Additional files
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